TARA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
23.2M
-0.7%
23.3M
+18.8%
19.6M
+2.9%
19.1M
+29.3%
14.8M
R&D
16.8M
-0.9%
17.0M
+25.0%
13.6M
+3.3%
13.1M
+36.8%
9.6M
SG&A
6.3M
-0.3%
6.4M
+5.0%
6.1M
+1.9%
6.0M
+15.2%
5.2M
Operating Income
-23154000
+0.7%
-23324000
-18.8%
-19629000
-2.9%
-19079000
-29.3%
-14760000
EBITDA
-23083000
+0.7%
-23252000
-19.0%
-19539000
-2.9%
-18986000
-29.4%
-14672000
Net Income
-21688000
-0.1%
-21668000
-21.9%
-17782000
-2.7%
-17307000
-30.5%
-13258000
EPS (Basic)
$-0.35
+2.8%
$-0.36
-16.1%
$-0.31
+18.4%
$-0.38
-22.6%
$-0.31
EPS (Diluted)
$-0.35
+2.8%
$-0.36
-16.1%
$-0.31
+18.4%
$-0.38
-22.6%
$-0.31
Shares (Diluted)
62.9M
+3.0%
61.0M
+6.0%
57.5M
+24.8%
46.1M
+9.0%
42.3M
Protara Therapeutics (TARA) — Financials